By Maksym Misichenko · Yahoo Finance ·
What AI agents think about this news
AdaptHealth's (AHCO) recent results show robust organic growth, but profitability is challenged by operational inefficiencies, manufacturer price hikes, and a reliance on capitated contracts. The company's pivot to a higher-margin Sleep/Respiratory business and expansion of capitation contracts is risky due to potential margin volatility and supplier leverage dynamics.
Risk: The increasing reliance on capitated contracts (now 14% of revenue) creates severe margin volatility when execution slips, and any supplier price increases could amplify this risk.
Opportunity: The successful scaling of the myAPP digital platform and workflow fixes could help offset structural cost inflation and improve margins.
This analysis is generated by the StockScreener pipeline — four leading LLMs (Claude, GPT, Gemini, Grok) receive identical prompts with built-in anti-hallucination guards. Read methodology →
Image source: The Motley Fool.
Tuesday, Aug. 4, 2026 at 8:30 a.m. ET
Operator: Good day, everyone, and welcome to today's AdaptHealth Second Quarter 2026 Earnings Release. Today's speaker will be Suzanne Foster, Chief Executive Officer of AdaptHealth; and Jason Clemens, Chief Financial Officer of AdaptHealth. Before we begin, I'd like to remind everyone that statements included in this conference call and in the press release issued today may constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act. These statements include, but are not limited to, comments regarding financial results for 2026 and beyond. Actual results could differ materially from those projected in forward-looking statements.
Because of a number of risk factors and uncertainties, which are discussed at length in the company's annual and quarterly SEC filings, AdaptHealth Corp. has no obligation to update the information provided on this call to reflect such subsequent events. Additionally, on this morning's call, the company will reference certain financial measures such as EBITDA, adjusted EBITDA, adjusted EBITDA margin and free cash flow, all of which are non-GAAP financial measures. You can find more information about these non-GAAP measures in the presentation materials accompanying today's call, which are posted on the company's website. This morning's call is being recorded, and a replay of the call will be available later today.
I'm now pleased to introduce the Chief Executive Officer of AdaptHealth, Suzanne Foster.
Suzanne Foster: Good morning, everyone, and thank you for joining our call today. I'm going to cover 3 topics this morning. First, we delivered 16% organic growth with record volumes gains across the business. Second, we made significant progress sharpening our portfolio and focusing on the core business, announcing the sale of our diabetes business, exiting other noncore products within Wellness-at-Home and contributing our e-commerce business into a new joint venture to improve how we serve the direct-to-consumer market. And third, I'll speak to 2 near-term profitability challenges we're navigating, our West Coast capitated contract and a material price increase from one of our largest manufacturers. Starting with our financial results.
Given the agreement we signed to divest our Diabetes Health business, I'll walk you through our results on a continuing operations basis, which excludes Diabetes Health included for prior year period comparisons. Revenue remains a bright spot. Second quarter net revenue from continuing operations was $740.3 million, up 12.7% versus the prior year quarter and 15.9% on an organic basis. Our West Coast capitated contract contributed 10.7 points of that organic growth with 5.2 points coming from our base business. Sleep Health net revenue was $386.5 million, up 15.5% versus the prior year. Respiratory Health net revenue was $194.4 million, up 14.1%. Wellness-at-Home net revenue was $159.4 million, up 4.9%.
Total capitated revenue grew to $103.3 million in the quarter and now represents approximately 14% of our continued operations net revenue. This is more than 3x the prior year with our West Coast capitated contract driving nearly all of that increase. Second quarter adjusted EBITDA from continuing operations was $132 million, with an adjusted EBITDA of 17.8%, driven by elevated West Coast capitated contract costs, which I'll speak to later. Now turning to the work we have done on simplifying and focusing our business.
Over the past 2 years, we have systematically reshaped AdaptHealth around our core sleep, respiratory and supporting home medical equipment businesses, the parts of our portfolio where we have the strongest value proposition and the clearest path to growth. In July, we took the most significant step yet in that effort. We signed a definitive agreement to sell our Diabetes Health business for $235 million, a move that we expect will ultimately improve our growth rate, enhance our margin profile and allow us to sidestep looming industry risks. We also took a further step in focusing our portfolio on the core by discontinuing proactive sales of certain product categories within our Wellness-at-Home segment.
This action removes nonstrategic, low-growth and low-margin product lines from our portfolio. And last week, we signed an agreement to contribute the CPAP Shop, a direct-to-consumer e-commerce business we've built within our sleep segment into a newly created joint venture with a leading e-commerce competitor and a telehealth prescriber network. The JV will have an unrivaled set of capabilities to fulfill its strategic ambition to reach the vast undiagnosed OSA population through home sleep testing and a digitally enabled path from diagnosis to treatment. Our growth strategy is focused on improving our service levels in our core business, expanding our capitated relationships where it makes sense and growing the number of large health systems we serve.
This quarter, we made progress on all 3 fronts. In May, we signed a new capitated agreement with Humana OneHome, successfully transitioning 478,000 new members in South Florida and Texas without disruption. Our capitated relationship with Humana now spans 33 states plus the District of Columbia and South Florida. We have a proven track record of successfully serving Humana patients under capitation over the past 3 years, and we're building on that experience as we take on this expansion. Our newly formed enterprise sales team exclusively focused on large health systems, secured preferred provider agreements with several multi-hospital health systems.
These customers recognize the clinical expertise we bring, the value of having our liaisons embedded in their systems to coordinate access to our services and care and the operational excellence that shapes how their patients experience it. Now let me turn to the more difficult part of the quarter, starting with the challenges we are facing with our West Coast capitated agreement. Having spent the first half of this year executing the largest patient transition in the history of home medical equipment, we spent the second quarter working to stabilize that operation on the West Coast.
Standing up a new geography this quickly, new buildings, new routes, new inventory, new people and a new customer relationship has posed new challenges, some of which we did not fully anticipate, but which have become clearer as the contract fully scaled. Throughout, we refused to compromise patient care and have remained fully committed to serving patients, whatever it took. With the benefit of a full quarter of operating this contract, here is what we know. Order volumes are running higher than expected, primarily in sleep resupply and enteral products. The outsized sleep resupply volume largely reflect transition-related pent-up demand and should prove transitory, while enteral volumes will require further intervention.
As we solve these 2 items, we believe gross margins will recover toward our original expectations. Second, there are inefficiencies in the inherited workflows, including the nonstandard use of urgent orders. These are contributing to unanticipated logistics costs downstream, which in turn have caused labor costs to remain elevated. We have met these elevated demands, but doing so at this level is not a sustainable model. We are working with our partner to align ordering practices with the original assumptions of the contract while rapidly introducing technology to streamline the workflows, shifting more of our fulfillment to drop ship rather than in-person delivery and rightsizing our fleet and labor accordingly.
The combination of these items represents $40 million of expected impact on profitability relative to our prior projections for the second half of this year. We remain confident that with sustained work and additional time, the contract will be a strong contributor to our profitability. Our long-term profitability outlook for the West Coast contract has always assumed we'd be able to use the footprint we built to serve additional business beyond the current capitated membership.
Currently, we are only able to serve our existing patients through our 40 new West Coast locations, and that will remain the case until the government-imposed DME moratorium put in place last February is lifted, and we can secure new PTANs, which are the Medicare billing numbers required to serve fee-for-service patients from these locations. Once that happens, we see substantial opportunity to serve patients who use our customers' health system but are insured through other payers and to sell proactively to other customers located near or within our new footprint. That incremental fee-for-service revenue will help absorb the fixed cost infrastructure we've built out on the West Coast.
To help offset the cost pressures I just described, we made the difficult decision in the second quarter to restructure our workforce, delivering $19 million in annualized savings while maintaining full operational delivery across every function. This required real sacrifice from our team who took on more so that we could continue serving patients without interruption. The other lever we're pulling on is technology, using it to fundamentally reengineer the patient journey from diagnosis to treatment, improving patient experience and accelerating cost efficiencies along the way. We are already seeing what a digitally enhanced patient experience looks like in practice. Our myAPP platform now connects nearly the entire patient journey. Let me walk you through it.
It starts with a digital front door. Patients can enter our platform before they are even officially a patient. It's as easy as scanning a QR code. From there, AI-powered intake walks them through insurance setup. They receive real-time order status tracking, and they can instantly self-schedule a virtual or in-person path setup without a phone call, order supplies in the app and access live or AI-powered chat support. And this quarter, we added our newest feature, an AI-powered mask fitting tool, which converted 92% of in-app scans to completed orders in its first 2 weeks. With early signs that it has reduced mask refittings that delay therapy.
These features and the ease of use are driving rapid adoption of myAPP, which with users standing at 512,000, up 56% since the end of 2025 and an app store rating of 4.8 stars. This and similar work to reengineer the patient and provider experience share a common thread. By removing the human intermediary, it frees up our people to focus on higher value, higher touch work and in return, supports our efforts to improve our cost basis. Addressing the key manufacturer price challenge I mentioned earlier, we were notified on June 30 by the manufacturer of their decision to terminate our contract and impose an immediate price increase effective July 1.
As it stands, this results in a $30 million impact in the second half of the year. We are actively working with the manufacturer to secure improved pricing and terms. But at this point, we've reflected the full impact in our outlook. That brings me to guidance. Our underlying base business continues to grow and is performing in line with our expectations. However, between the portfolio actions we've taken, the challenges we currently have with our West Coast capitated contract as well as the manufacturer's price increase, we must reset our full year outlook. Let me close with how we're thinking about the road ahead.
Everything we are doing is to enhance the important role we play within a critical part of the health care ecosystem upon which millions of patients depend. The portfolio actions we've completed position us as a more focused company built around Sleep and Respiratory, where we have the strongest value proposition. Our rapid growth demonstrates that health care providers see the clinical and economic value of the services we provide. And in addition, with all the realities facing our industry, we are well positioned to benefit from the industry's ongoing consolidation with the size and scale to take on significant volume. We acknowledge that growing this fast over a period -- short period of time has stressed our cost structure.
These near-term pains come with a silver lining. Our growth is pushing us to think differently, to leverage technology and innovate in ways we never thought possible. These innovations are benefiting patients and providers today and over time, will lower our cost to serve. Ultimately, these growing pains will make us a stronger, more efficient company. And with that, let me turn it over to Jason to review the financials.
Jason Clemens: Thank you, Suzanne, and thanks to everyone for joining our call today. I'll cover our second quarter financial results, followed by a review of our balance sheet, capital allocation and outlook. As Suzanne noted, given our agreement to divest Diabetes Health, all figures I'll discuss are on a continuing operations basis, including prior period comparisons, unless otherwise noted. For the second quarter, net revenue of $740.3 million increased 12.6% versus the prior year quarter with organic growth of 15.9%. Second quarter adjusted EBITDA was $132.0 million versus $136.4 million for the prior year quarter. As Suzanne discussed, this reflects continued elevated costs associated with the West Coast capitated contract ramp. Second quarter adjusted EBITDA margin was 17.8%.
Discontinued operations produced approximately $23 million of adjusted EBITDA, covering $14 million of corporate overhead expenses that remain in continuing operations. The West Coast capitated contract missed our expectations by $15 million, so we are adjusting for this run rate in full year guidance that I will cover later. Turning to the balance sheet and cash flows. We ended the quarter with a consolidated total leverage ratio of 3.06x. After quarter end, we triggered the $325 million delayed draw term loan secured as part of our April refinancing and used the proceeds to redeem our 6.125% senior notes due 2028. This action eliminated our highest cost tranche of debt and extended our overall maturity.
We intend to prioritize repayment of our revolving credit facility over the remainder of the year and remain committed to our net leverage target of 2.5x. We intend to direct a significant portion of the proceeds from the Diabetes Health divestiture to further debt reduction. Regarding goodwill, the Diabetes Health divestiture required us to reallocate shared corporate costs previously carried by that segment across our remaining reporting segments and the resulting revision to Respiratory Health
Four leading AI models discuss this article
"Near-term cost overruns and execution risks from aggressive capitated growth outweigh organic momentum, likely pressuring AHCO shares until West Coast stabilization is proven."
AHCO's Q2 2026 results show robust 15.9% organic revenue growth ($740M) driven by capitated contracts now at 14% of revenue, but adjusted EBITDA fell to $132M (17.8% margin) amid $40M West Coast contract inefficiencies, a $30M manufacturer price hike, and restructuring. Portfolio pruning (diabetes sale for $235M, Wellness exits, e-commerce JV) sharpens focus on sleep/respiratory but highlights execution risks in rapid scaling. Leverage at 3.06x with debt paydown plans offers some buffer, yet near-term profitability reset signals growing pains. Technology initiatives (myAPP adoption +56%) are promising but unproven at scale for margin recovery.
The $70M combined headwinds may prove stickier than management admits; if the DME moratorium persists, West Coast fixed costs stay unabsorbed, enteral volume interventions fail, and supplier pricing pressure spreads, margins could compress further and debt reduction targets slip.
"The company's inability to control operational costs during rapid expansion suggests that management is prioritizing top-line growth at the expense of sustainable profitability."
AdaptHealth is in a classic 'growth-at-any-cost' trap. While 15.9% organic growth is impressive, the $70 million in combined headwinds—$40 million from operational inefficiencies in the West Coast capitated contract and $30 million from a sudden manufacturer price hike—reveals a fragile business model. The reliance on capitated contracts (now 14% of revenue) creates severe margin volatility when execution slips. While divestitures and tech-driven cost-cutting are logical, they are reactive measures to cover structural cracks. Until the company demonstrates it can scale these massive contracts without blowing up its EBITDA margins, the risk-reward profile remains unattractive despite the recent debt refinancing.
If the West Coast contract stabilizes and the DME moratorium lifts, the company could see massive operating leverage as they finally utilize their built-out infrastructure for fee-for-service patients.
"AHCO's growth is real (15.9% organic), but profitability is being crushed by two non-recurring but material shocks ($40M West Coast + $30M pricing) that could persist into 2027 if operational fixes and regulatory relief don't materialize on schedule."
AHCO is executing a high-risk, high-reward pivot. The 16% organic growth and portfolio streamlining (divesting Diabetes, JV-ing CPAP Shop) signal disciplined capital allocation. But the West Coast capitated contract is a $40M profitability headwind in H2 2026 alone—that's material enough to wipe out margin expansion. The $30M manufacturer price shock adds insult. Management frames these as 'growing pains,' but the real test is whether the myAPP digital platform and workflow fixes materialize fast enough to offset structural cost inflation. The DME moratorium lifting is binary and outside management's control.
If the West Coast contract doesn't stabilize by Q4, and the manufacturer doesn't negotiate better terms, AHCO could face covenant pressure or forced asset sales beyond Diabetes Health. The 'silver lining' narrative about innovation-driven efficiency gains is aspirational—execution risk is real.
"AHCO’s upside depends on stabilizing the West Coast capitated contract and delivering the $40m margin tailwinds from cost cuts and tech, otherwise near-term headwinds may limit the earnings uplift from the strategic reshaping."
AdaptHealth is pivoting toward a higher-margin core Sleep/Respiratory business and expanding capitation (Humana) while divesting Diabetes Health and pursuing a CPAP Shop JV. Near-term catalysts include cost cuts ($19m annualized) and tech-driven efficiency via myAPP, but the firm flags a $40m profitability drag from the West Coast capitated contract and a $30m supplier price increase in H2. The earnings path hinges on stabilizing the West Coast ramp and converting transitional cost savings into sustained margin expansion, plus upside from incremental fee-for-service and non-capitated demand once regulatory hurdles lift. Leverage remains a concern at ~3.1x, even after debt actions.
The West Coast ramp could prove stickier than guidance suggests, turning the $40m drag into a longer-term headwind. Divesting Diabetes Health also reduces diversification, leaving AHCO more exposed to capitation and payer mix risk if the tailwinds fade.
"Manufacturer pricing pressure risks spreading, compounding capitation-driven margin volatility beyond isolated headwinds."
Claude correctly flags the binary DME moratorium risk, but nobody has connected the $30M manufacturer price shock to potential spread across other suppliers. With capitated contracts now at 14% of revenue, any contagion would amplify margin volatility far beyond the isolated West Coast $40M drag. This supplier leverage dynamic could force renegotiation of capitation rates or accelerated divestitures.
"Divesting the Diabetes segment concentrates AHCO's revenue into a narrower, more volatile risk profile, leaving them vulnerable to supplier pricing pressure without the buffer of a diversified business mix."
Grok, you're right about supplier contagion, but you’re missing the secondary risk: the divestiture of the Diabetes business. By shedding that segment, AHCO is concentrating its revenue mix into a narrower, more volatile bucket just as supplier leverage shifts. This creates a 'concentration trap.' If the Sleep/Respiratory segment faces further manufacturer pricing pressure, they have fewer diversified cash flows to subsidize the margin compression. This isn't just a pivot; it's a narrowing of the safety margin.
"AHCO is concentrating into its highest-volatility revenue stream precisely when capitation penetration accelerates, not diversifying away from it."
Gemini's concentration trap is real, but it undershoots the actual risk. AHCO isn't just narrowing into Sleep/Respiratory—it's narrowing into a segment where capitation penetration is rising fastest. If West Coast stabilizes but Sleep/Respiratory capitated volumes scale faster than fee-for-service, the entire margin profile locks into a high-volatility, low-flexibility state. Portfolio pruning made sense; timing it into peak capitation adoption didn't.
"Capitation-driven revenue share creates outsized EBITDA risk from payer dynamics, not just the West Coast drag."
Grok, you’re right to flag supplier contagion risk from price shocks, but the bigger structural risk is payer mix sensitivity as capitation climbs. If 14% of revenue becomes increasingly dependent on capitated deals, any acceleration in capitation costs or payer negotiation power would disproportionately hit EBITDA, not just gross margin. Margin recovery hinges on scaled cost takeout from myAPP and operational leverage, which remains unproven at scale and under current mix.
AdaptHealth's (AHCO) recent results show robust organic growth, but profitability is challenged by operational inefficiencies, manufacturer price hikes, and a reliance on capitated contracts. The company's pivot to a higher-margin Sleep/Respiratory business and expansion of capitation contracts is risky due to potential margin volatility and supplier leverage dynamics.
The successful scaling of the myAPP digital platform and workflow fixes could help offset structural cost inflation and improve margins.
The increasing reliance on capitated contracts (now 14% of revenue) creates severe margin volatility when execution slips, and any supplier price increases could amplify this risk.